CC vs. HUN, BCPC, ASH, IOSP, NGVT, OLN, HWKN, PRM, FMC, and FUL
Should you be buying Chemours stock or one of its competitors? The main competitors of Chemours include Huntsman (HUN), Balchem (BCPC), Ashland (ASH), Innospec (IOSP), Ingevity (NGVT), Olin (OLN), Hawkins (HWKN), Perimeter Solutions (PRM), FMC (FMC), and H.B. Fuller (FUL). These companies are all part of the "basic materials" sector.
Huntsman (NYSE:HUN) and Chemours (NYSE:CC) are both mid-cap basic materials companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
84.8% of Huntsman shares are owned by institutional investors. Comparatively, 76.3% of Chemours shares are owned by institutional investors. 6.1% of Huntsman shares are owned by insiders. Comparatively, 0.5% of Chemours shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Huntsman pays an annual dividend of $1.00 per share and has a dividend yield of 4.0%. Chemours pays an annual dividend of $1.00 per share and has a dividend yield of 3.5%. Huntsman pays out -192.3% of its earnings in the form of a dividend. Chemours pays out -46.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Huntsman has increased its dividend for 4 consecutive years. Huntsman is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Huntsman has higher revenue and earnings than Chemours. Huntsman is trading at a lower price-to-earnings ratio than Chemours, indicating that it is currently the more affordable of the two stocks.
Huntsman presently has a consensus target price of $26.73, suggesting a potential upside of 7.49%. Chemours has a consensus target price of $31.63, suggesting a potential upside of 11.24%. Given Huntsman's stronger consensus rating and higher possible upside, analysts plainly believe Chemours is more favorable than Huntsman.
In the previous week, Huntsman had 11 more articles in the media than Chemours. MarketBeat recorded 28 mentions for Huntsman and 17 mentions for Chemours. Chemours' average media sentiment score of 0.37 beat Huntsman's score of 0.11 indicating that Huntsman is being referred to more favorably in the media.
Chemours received 7 more outperform votes than Huntsman when rated by MarketBeat users. However, 66.49% of users gave Huntsman an outperform vote while only 61.01% of users gave Chemours an outperform vote.
Huntsman has a net margin of -1.49% compared to Huntsman's net margin of -5.51%. Huntsman's return on equity of 46.67% beat Chemours' return on equity.
Huntsman has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Chemours has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.
Summary
Huntsman beats Chemours on 13 of the 21 factors compared between the two stocks.
Get Chemours News Delivered to You Automatically
Sign up to receive the latest news and ratings for CC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemours Competitors List
Related Companies and Tools
